Document:

<Page>

                                                                   EXHIBIT 10.12

Seasons

                                                            RESIDENTIAL PROPERTY

                          PROPERTY MANAGEMENT AGREEMENT

This Agreement is made as of the 1st day of January, 2002 between the
undersigned, Seasons of Laurel, L.L.C., a Delaware limited liability company,
(the "Owner") and the undersigned BRI OP LIMITED PARTNERSHIP, (the "Agent").

     1.  APPOINTMENT AND ACCEPTANCE. The Owner appoints the Agent as exclusive
agent for the management of the property described in Section 2 of this
Agreement, and the Agent accepts the appointment, subject to the terms and
conditions set forth in this Agreement.

     2.  DESCRIPTION OF THE PROJECT. The property to be managed by the Agent
under this Agreement (the "Project") is a housing development consisting of the
land, buildings, and other improvements located in Laurel, Maryland and known as
The Seasons Apartments, containing 1,088 dwelling units.

     3.  BASIC INFORMATION. The Agent will thoroughly familiarize itself with
the character, location, construction, layout, plan and operation of the
Project, and especially the electrical, plumbing, air-conditioning and
ventilating systems, the elevators and all other mechanical equipment.

     4.  MARKETING. The Agent will carry out the marketing activities designed
to attract tenants as described below.

     5.  RENTALS. The Agent will offer for rent and will rent the dwelling units
and commercial space, if any, in the Project. Incident thereto, the following
provisions will apply:

     a.  The Agent will show the Project to prospective tenants;

     b.  The Agent will take and process applications for rentals. If an
         application is rejected, the applicant will be told the reason for
         rejection, and will be given the rejected application, with reason for
         rejection noted. A current list of prospective tenants will be
         maintained;

     c.  The Agent will prepare all dwelling leases and, unless otherwise
         directed by the Owner, will execute the same in its name, identifying
         itself thereon as agent for the Owner. Dwelling leases will be in a
         form approved by the Owner;

     d.  The Owner will furnish the Agent with rent schedules, showing contract
         rents for dwelling units, and other charges for facilities and
         services. The Agent will periodically review such rent schedules and
         make recommendations to the Owner with respect to changes thereto;

<Page>

                                        2

     e.  The Agent will collect, deposit, and disburse security deposits, if
         required, in accordance with the terms of each tenant's lease;

     f.  The Agent will negotiate and prepare commercial leases and concession
         agreements, if the Project shall now or hereafter contain any
         commercial space, and will execute the same in its name, identified
         thereon as agent for the Owner, subject to the Owner's prior approval
         of all terms and conditions; and

     g.  The Agent will perform periodic market surveys with respect to the
         market area in which the Project is located.

     6.  COLLECTION OF RENTS AND OTHER RECEIPTS. The Agent will collect, when
due, all rents, charges and other amounts receivable for the Owner's account in
connection with the management and operation of the Project. Such receipts will
be deposited in an account, separate from all other accounts and funds, with a
bank whose deposits are insured by the Federal Deposit Insurance Corporation.
This account will be carried in the Owner's name and designated of record as
Seasons of Laurel, L.L.C. d/b/a "The Seasons Apartments" (the "Project Rental
Account"). Subject to compliance with Section 11 hereof, the Agent is, however,
hereby authorized to make deposits to and withdrawals from the Project Rental
Account as agent for the Owner.

     7.  ENFORCEMENT OF LEASES. The Agent will secure full compliance by each
tenant with the terms of such tenant's lease. Voluntary compliance will be
emphasized, but the Agent may lawfully terminate any tenancy when, in the
Agent's judgment, sufficient cause (including but not limited to non-payment of
rent) for such termination occurs under the terms of the tenant's lease. For
this purpose, the Agent is authorized to consult with legal counsel, to be
designated by the Owner, to bring actions for eviction against such tenants;
provided, however, the Agent shall keep the Owner informed of such actions and
shall follow such instructions as the Owner may prescribe for the conduct of any
such action. Subject to the Owner's approval, attorney fees and other necessary
costs incurred in connection with such actions will be paid out of the Project
Rental Account as Project expenses.

     8.  MAINTENANCE AND REPAIR. The Agent will maintain the Project in good
repair and in compliance with local codes, and in a condition at all times
acceptable to the Owner, including, but not limited to, cleaning, painting,
decorating, plumbing, carpentry, grounds care, and such other maintenance,
repair, remodeling and refurbishing work as may be necessary, subject to any
limitations imposed by the Owner in addition to those contained herein. The
Agent will also assist the Owner in identifying and implementing capital
improvements to the Project. The Agent will perform such periodic physical
inspections as shall be appropriate in connection therewith. Incident thereto,
the following additional provisions will apply:

     a.  Special attention will be given to preventive maintenance, and, to the
         extent feasible, the services of regular maintenance employees will be
         used;

<Page>

                                        3

     b.  Subject to the Owner's prior approval, the Agent will negotiate, review
         and sign, on behalf of the Owner, contracts with qualified independent
         contractors for the maintenance and repair of heating and
         air-conditioning systems and elevators, and for extraordinary repairs
         to such items and other assets of the Project, which are beyond the
         capability of regular maintenance employees;

     c.  The Agent will systematically and promptly receive and investigate all
         service requests from tenants, take such action thereon as may be
         justified, and will keep records of the same. Emergency requests will
         be received and serviced on a twenty-four (24) hour basis. Complaints
         of a serious nature will be reported to the Owner after investigation;

     d.  The Agent is authorized to purchase all materials, equipment, tools,
         appliances, supplies and services necessary to the proper maintenance
         and repair of the Project; and

     e.  Notwithstanding any of the foregoing provisions, the prior approval of
         the Owner will be required for any expenditure which exceeds Five
         Thousand Dollars ($5,000) in any one instance for labor, materials or
         otherwise, in connection with the maintenance and repair of the
         Project, except for recurring expenses within the limits of the
         operating budget and emergency repairs involving manifest danger to
         persons or property or required to avoid suspension of any necessary
         service to the Project. In the latter event, the Agent will inform the
         Owner of the facts as promptly as possible.

     9.  UTILITIES AND SERVICES. In accordance with the operating budget, the
Agent will make arrangements for water, electricity, gas, sewage and trash
disposal, vermin extermination, decorating, laundry facilities, and telephone
service. Subject to the Owner's prior approval, the Agent will make such
contracts as may be necessary to secure such utilities and services.

     10. NONCUSTOMARY SERVICES. Notwithstanding any contrary provision in this
Agreement, the Owner shall cause any services, in connection with the rental of
the Project, that are not customarily furnished to tenants of comparable
buildings in the region (including, but not limited to, the provision of maid
service and the furnishing of parking facilities, other than on a complimentary,
unreserved basis), to be performed by an entity qualifying as an independent
contractor.

     11. EMPLOYEES. Except as otherwise agreed, all on-site personnel will be
employees of the Owner, for purposes of their compensation, and not the Agent,
but will be hired, paid, supervised, and discharged through the Agent, in the
Agent's sole discretion, subject to the following conditions:

     a.  The resident manager will have duties of the type usually associated
         with this position;

<Page>

                                        4

     b.  Compensation (including fringe benefits) of bookkeeping, clerical, and
         other managerial personnel will be within the Agent's sole discretion,
         provided minimum wage standards are met;

     c.  The Owner will reimburse the Agent for the compensation (including
         fringe benefits) payable to the on-site management and maintenance
         employees, and for all local, state and federal taxes and assessments
         (including, but not limited to, Social Security taxes, unemployment
         insurance, and Workman's Compensation insurance) incident to the
         employment of such personnel. Such reimbursements will be paid out of
         the Project Rental Account and will be treated as Project expenses; and

     d.  Compensation (including fringe benefits) payable to the on-site staff,
         and all bookkeeping, clerical and other managerial personnel, plus all
         local, state and federal taxes and assessments incident to the
         employment of such personnel will be borne solely by the Project, and
         will not be paid out of the Agent's management fee. The rental value of
         any dwelling unit furnished rent-free to on-site personnel will be
         treated as a cost of the Project.

     12. DISBURSEMENTS FROM PROJECT RENTAL ACCOUNT.

     a.  From the funds collected and deposited by the Agent in the Project
         Rental Account, either the Owner or the Agent, as shall be determined
         from time to time by the Owner, will make the following disbursements,
         when payable:

         (1)   Reimbursement to the Agent for compensation payable to the
               employees specified in Section 11 above, and for the taxes and
               assessments payable to local, state and federal governmental
               agencies;

         (2)   All sums otherwise due and payable by the Owner as expenses of
               the Project, including compensation payable to the Agent for its
               services hereunder and expenses of the Project incurred by the
               Agent under the terms of this Agreement;

         (3)   Any payment required to be made monthly by the Owner to any
               mortgagee of the Project, including the amounts due under the
               mortgage for principal amortization, interest, ground rents,
               taxes and assessments, and fire and other hazard insurance
               premiums;

     b.  Except for the disbursements mentioned above, funds will be disbursed
         or transferred from the Project Rental Account only as the Owner may
         from time to time direct; and

     c.  In the event the balance in the Project Rental Account is at any time
         insufficient to pay disbursements due and payable under Section 12(a)
         above, the Agent will inform the

<Page>

                                        5

         Owner of that fact and Owner shall immediately deposit sufficient
         funds. In no event will the Agent be required to use its own funds to
         pay such disbursements.

     13. RECORDS AND REPORTS. The Agent will have the following responsibilities
with respect to records and reports:

     a.  The Agent will establish and maintain a comprehensive system of
         records, books and accounts in a manner satisfactory to the Owner;

     b.  With respect to each fiscal year ending during the term of this
         Agreement, the Agent will furnish an annual financial report. The Agent
         will also prepare and review budgets and cash flow projections for the
         Project in such manner and at such times as may be agreed with the
         Owner;

     c.  The Agent will furnish such information (including occupancy reports)
         as may be reasonably requested by the Owner from time to time with
         respect to the financial, physical, or operating condition of the
         Project; and

     d.  By the twenty-fifth (25th) day of each month, the Agent will furnish
         the Owner with a statement of receipts and disbursements during the
         previous month, a schedule of accounts receivable and payable, as of
         the end of the previous month and reconciled bank statements for the
         Project Rental Account, as of the end of the previous month.

     14. ON-SITE MANAGEMENT FACILITIES. Subject to the further agreement of the
Owner and the Agent as to more specific terms, the Agent will maintain a
management office within the Project, for the convenience of the Owner, for the
sole purpose of the Agent's performing its duties under this Agreement, and the
Owner will make no rental charge for such office.

     15. INSURANCE. The Owner will inform the Agent of insurance to be carried
with respect to the Project and its operations, and the Agent, when authorized
by the Owner, will cause such insurance to be placed and kept in effect at all
times. The Agent will pay premiums out of the Project Rental Account, as an
expense of the Project. All insurance will be placed with such companies, on
such conditions, in such amounts, and with such beneficial interests appearing
thereon as shall be acceptable to the Owner and shall be otherwise in conformity
with any mortgage relating to the Project, provided that the same will include
public liability coverage, with the Agent designated as one of the insured, in
amounts acceptable to the Owner, Agent and any mortgagee of the Project. The
Agent will investigate and furnish the Owner with full reports as to all
accidents, claims, and potential claims for damage relating to the Project and
will cooperate with the Owner's insurers in connection therewith.

     16. AGENT'S COMPENSATION. The Agent will be compensated for its service
under this Agreement by monthly fees to be paid out of the Project Rental
Account to be treated as

<Page>

                                        6

Project expenses. Such fees will be payable monthly. Each such monthly fee will
be in an amount equal to five percent (5%) of the gross receipts (including
rentals and other operating income of the Project) actually received during the
preceding month.

     17. INDEMNIFICATION BY THE OWNER. The Owner shall indemnify and hold
harmless the Agent from all liability, claims, damages or loss arising out of
the performance of its duties hereunder, and related expenses, including
reasonable attorneys' fees, to the extent such liability, claims, damages or
losses and related expenses are not fully reimbursed by insurance; provided,
however, that the Agent shall be entitled to indemnification, under this Section
17, only if the Agent, in connection with any liability, damages, claim or loss
for which it seeks indemnity, acted in a manner which would not constitute gross
negligence or willful misfeasance.

     18. INDEMNIFICATION BY THE AGENT. The Agent shall indemnify and hold
harmless the Owner from contract or other liability, claims, damages, losses and
related expenses, including attorneys' fees, to the extent that such liability,
claims, damages, losses and related expenses are not fully reimbursed by
insurance and are incurred by the Owner by reason of the Agent's deliberate
dishonesty or gross negligence.

     19. RIGHT TO ASSIGN. The Agent may assign some or all of its rights or
obligations under this Agreement, provided that the Agent remains principally
responsible hereunder, and the Owner is given notice of such assignment. The
Owner may assign its rights and obligations under this Agreement to any
successor in title to the Property, and upon any such assignment, the Owner
shall be relived of all liability accruing after the effective date of such
assignment.

     20. TERM OF AGREEMENT. This agreement shall be in effect for a period
commencing on the date hereof. This agreement may be terminated, without
penalty, by written notice of either party to the other as of the end of any
calendar month, provided at least thirty (30) days advance notice thereof is
given.

     IN WITNESS WHEREOF, the parties hereto (by their duly authorized
representatives) have executed this Agreement as of the date first above
written.

OWNER:                                   AGENT:

SEASONS OF LAUREL, L.L.C.                BRI OP LIMITED PARTNERSHIP
                                         By:  Berkshire Apartments, L.L.C., its
                                         general partner
By: /s/ David C. Quade
    ---------------------
Its:
                                         By: /s/ David Olney
                                             ---------------------------------
                                         Its:Exhibit 10.20  

[Portions of this Exhibit have been omitted pursuant to a request for confidentiality under Rule 406 of the Securities Act of 1933, as amended. A copy of this
Exhibit with all sections intact has been filed separately with the Securities and Exchange Commission.]

Amendment No. 4

to the

License Agreement

dated 13th of June 2000 (the "Agreement") by and between

Antares Pharma IPL AG, Zug, Switzerland as Licensor

(formerly known as Permatec Technologie AG)

and

BioSante Pharmaceuticals, Inc., Lincolnshire, IL, U.S.A. as Licensee  

WHEREAS, Antares Pharma IPL AG, Zug, Switzerland ("Antares") and BioSante Pharmaceuticals, Inc. ("BioSante") have previously
entered into a License Agreement dated June 13, 2000 ("Agreement"), regarding the grant of a license with the right to sublicense specified products, as well as a Supply Agreement of the same
date; and 

WHEREAS, Antares and BioSante have also entered into a series of three amendatory agreements subsequent to June 13, 2000, each of which has made
specified amendments to the terms of the Agreement, as follows: Amendment No. 1, dated May 20, 2001; Amendment No. 2, dated July 5, 2001; and Amendment No. 3, dated
August 30, 2001; and 

WHEREAS, Antares and BioSante each acknowledge that the other is, as of this date, in material compliance with all aspects of the License Agreement and
Supply Agreement, but that Antares and BioSante have identified issues involving interpretation of the Agreement and the amendments regarding which they disagree, including issues relating to the
Products covered by the Agreement, and desire to resolve those differences and continue their business relationship subject to some altered terms; and 

WHEREAS, in order to effectuate these purposes, Antares and BioSante desire to enter into an agreement that will effectuate a fourth set of amendments
to the Agreement, with the terms set forth below; 

NOW THEREFORE, the Parties hereby agree pursuant to this Amendment No. 4 to the License Agreement dated 13th of June 2000
("Amendment No. 4") to amend the Agreement as follows: 

I.    Amendments to Agreement

[I-1]
Covered Products 

Paragraph 2.1
License, as amended by Amendment No. 1, is further modified to provide that BioSante is granted a license, with the right to
grant sublicenses, to Develop the Products and any improvements or modifications thereof created, developed or devised by BioSante or Antares. It therefore follows that: 

        A.    The
Products include all estrogen gels, all testosterone gels, all E+T gels, and all E+P gels, whether or not their formulations contain XXXXXXXXXXX, except as noted in B
below; [A portion of this section has been omitted pursuant to a request for confidential treatment under Rule 406 under the Securities Act of 1933, as
amended. A copy of this section with the portion intact has been filed separately with the Securities and Exchange Commission]

        B.    BioSante
owns, on an exclusive worldwide basis all rights to Bio-T-Gel, the XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX, and has no obligation to share any information regarding
Bio-T-Gel with Antares, including data generated during development; [A portion of this section has been omitted pursuant to a request for confidential treatment
under Rule  

 

 406 under the Securities Act of 1933, as amended. A copy of this section with the portion intact has been filed separately with the Securities and Exchange
Commission]

[I-2]
Assistance 

I-2-1
Paragraph 2.3 Assistance: Paragraph 2.3 Assistance of the Agreement is amended by the addition of an alternative means for Antares to
provide assistance, as follows: if and when requested by BioSante in its sole discretion, provision of assistance will be negotiated on a project basis with an agreed-upon budget before the work
commences. The final charges will be based on this budget only and will be invoiced at +/- 10% of the agreed upon budget. No additional work beyond the agreed project will commence, nor charges
reimbursed, without the written agreement of Antares and BioSante. 

I-2-2
Manufacturing Assistance Agreement: The parties acknowledge and agree that the Manufacturing Assistance Agreement between the parties creation of
which was provided for by Amendment No.3 has not been created, and that, as a result of different agreements of the parties embodied in this Amendment no.4, the parties no longer desire
that such a Manufacturing Assistance Agreement should be created or entered into between them. 

[I-3]
Royalty 

Paragraph 3.2
Roya1ty Payments of the Agreement, as amended by Amendment No. 3, is further amended to provide that BioSante's obligation
to pay a royalty is amended from XXXXXX (XXX) to XXXXXXX (XXX) in the case of licensed Products, and BioSante will pay to Antares a royalty of XXX of the royalty received by BioSante, up to a maximum
of XXXX of net sales, in the case of sub-licensed Products. [A portion of this section has been omitted pursuant to a request for confidential treatment under Rule
406 under the Securities Act of 1933, as amended. A copy of this section with the portion intact has been filed separately with the Securities and Exchange
Commission]

[I-4]
Sub-licensee up-front, sublicense or milestone payments 

Paragraph 3.4
of the Agreement is amended to provide that: 

        A.    Upon
sub-license by BioSante of any Product covered in this Agreement or Amendments Nos. 1, 2, or 3 (other than XXXXX), BioSante will pay to Antares the proportion
of such upfront payments defined in C below or Milestone Payments defined in paragraph 3.3 actually received, as follows: a) where the payments received by BioSante are XXXXXXXXXXXX from
BioSante to Antares then XXXXXXXXXX will be due to Antares, b) where the payments to BioSante arc XXXXXXXXXXXXXXX above the commitment to Antares, the additional amount payable to Antares will
be XXX of this excess, and c) where payments received by BioSante are XXXXXXXXXXX the amounts due to Antares, then BioSante will pay Antares XXX of this excess. (For example, if a Milestone Payment of
XXXXXX is due from BioSante to Antares, and a sub-licensee pays BioSante a Milestone Payment upon the same milestone of XXXXXX, BioSante will pay
Antares XXX of the amount from XXXXXX to XXXXXX (that is, XXXXXX) and BioSante will pay Antares XXX of the XXXXXX excess over XXXXXXXXXXX the XXXXXX Milestone Payment, or XXXXXX) for a total of
XXXXXX; [A portion of this section has been omitted pursuant to a request for confidential treatment under Rule 406 under the Securities Act of 1933, as
amended. A copy of this section with the portion intact has been filed separately with the Securities and Exchange Commission]

        B.    In
the case of XXXX, BioSante will pay to Antares XXX of all sums received from sub-licensees for the same Milestone in excess of the Milestone Payment payable under
paragraph 3.3; [A portion of this section has been omitted pursuant to a request for confidential treatment under Rule 406 under the Securities Act of 1933, as
amended. A copy of this section with the portion intact has been filed separately with the Securities and Exchange Commission]

2

 

        C.    For
purposes of calculating the appropriate amount of upfront payments, Antares and BioSante agree that the $1.0 million BioSante paid upfront to Antares is deemed
to be attributed XXXXXXX to each of Bio-E-Gel, LibiGel and XXXX (XXXXXXXX); [A portion of this section has been omitted pursuant to a request for confidential
treatment under Rule 406 under the Securities Act of 1933, as amended. A copy of this section with the portion intact has been filed separately with the Securities and Exchange
Commission]

        D.    BioSante
has no obligation to pay to Antares any portion of payments made to it for equity investments by sub-licensees, except to the extent that such equity investment
incorporates payment of a per-share premium over the then-current market price, in which case BioSante shall pay Antares XXX of such premiums received. [A portion
of this section has been omitted pursuant to a request for confidential treatment under Rule 406 under the Securities Act of 1933, as amended. A copy of this section with the portion intact has been
filed separately with the Securities and Exchange Commission]

[I-5]
BioSante's Development and Marketing obligations/United States and Non-US 

Paragraphs 5.3
BioSante's Development and Marketing obligations/United States and 5.4 BioSante's Development and
Marketing obligations/Non-US are amplified by the agreement that at its risk, BioSante will make final decisions as to data requirements for US submissions. 

[I.6]
Reduction in Royalty 

Paragraph 8.2.3
Reduction in Royalty is amended to provide that in the instance in which arise the triggering circumstances described in that
Paragraph 8.2.3, relating to the existence an A/B rated generic
equivalent, the royalty owing is to be reduced from XXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXX. [A portion of this section has been omitted pursuant to a request
for confidential treatment under Rule 406 under the Securities Act of 1933, as amended. A copy of this section with the portion intact has been filed separately with the Securities and Exchange
Commission]

[I-7]
Terms 

Paragraph 10.3.2
Terms, regarding XXX Combi Gel is amended to provide that 

        A.    the
license fee totals XXXXXXXXXXXXXXXXXXXXXXXXXX (XXXXXX); and 

        B.    XXXXXXXXXXXXXXXXXXXXXXXX
(XXXXXX) of the license fee has been satisfied by Amendment No. 1, and royalty to XXX from XXX. 

[A portion of these sections have been omitted pursuant to a request for confidential treatment under Rule 406 under the Securities Act of 1933, as amended.
A copy of these sections with the portion intact has been filed separately with the Securities and Exchange Commission]

[I-8]
Payments 

I-8-1
10.3.3.2 Manufacturing of clinical batches: The provisions of sub-paragraph 10.3.3.2 of the Agreement are entirely deleted, extinguished
and eliminated. 

I-8-2
10.3.3.3 Filing of the product: The provisions of sub-paragraph 10.3.3.3 are amended to provide that the maximum milestone payment owed by
BioSante upon filing of the product is XXXXXXXXXXXXXXXXXXXXX (XXXXXX). [A portion of this section has been omitted pursuant to a request for confidential treatment
under Rule 406 under the Securities Act of 1933, as amended. A copy of this section with the portion intact has been filed separately with the Securities and Exchange
Commission]

3

 

II.    Supply Agreement

[II-1]
Supply Agreement Termination 

The
Supply Agreement between Antares (formerly known as Permatec Technologie, AG) and BioSante dated June 13, 2000, by agreement of Antares and BioSante, is hereby terminated, extinguished an
eliminated in its entirety pursuant to Article 18 (Modification) of the Supply Agreement. Antares and BioSante acknowledge that all manufacturing is being transferred to a U.S. based GMP
manufacturer and that Antares has no similar capacity. Any assistance in manufacturing will be governed by Paragraph 2.3 as amended above. Antares and BioSante each acknowledge that
(a) neither has accrued any rights to its benefit under the Supply Agreement prior to this date, and that (b) neither has any obligations under the Supply Agreement that survive this
termination 

[II-2]
Antares to Involve BioSante in Manufacturing Communications 

In
order to maintain efficiency and accuracy in manufacturing, which will benefit both Antares and BioSante, Antares agrees to assure that BioSante will be fully involved and informed in conversations
and communications with XXXXXXXXXXX regarding BioSante products, Bio-E-Gel, LibiGel, LibiGel E/T and any other product that may be developed. [A portion of this
section has been omitted pursuant to a request for confidential treatment under Rule 406 under the Securities Act of 1933, as amended. A copy of this section with the portion intact has been
filed separately with the Securities and Exchange Commission]

III.    General

[III-
1] Package Development 

In
the event that another Antares licensee uses a package or labeling developed by BioSante, BioSante will be reimbursed by Antares for development expenses in an amount to be negotiated by the
parties in good faith. In the event another Antares licensee uses packaging for which BioSante provides dies, tooling, and similar equipment, BioSante will be reimbursed by Antares for the expense of
such equipment. 

[III-2]
Governance 

In
addition to and preceding the mechanisms in 11.2 Dispute Resolution of the Agreement, the parties agree that Steering Committee, made up of Dario
Cararra, Roger Harrison, Stephen Simes and Leah Lehman or replacements to be named by the respective companies. The Operational Committee will be Holger, Doris and Lisa or replacements to be named by
the respective companies. 

[III-3]
Continued effect 

The
parties agree that the Agreement shall, except for and in due incorporation of the amendments agreed upon in Amendment No. 1, dated May 20,2001; Amendment No. 2 dated
July 5,2001; and Amendment No.3, dated August 30, 2001, and this Amendment No. 4, remains in full force and effect and are not otherwise changed, altered or amended. The parties
further agree that in the event that any further amendment, change or alteration to the language or wording if any section of the Agreement or this Amendment No.4 is determined by the parties to be
required to give full effect to any of the changes agreed upon in this Amendment No. 4, then the parties agree to execute in writing any such further amendment, change or alteration. 

4

 

IN WITNESSETH WHEREOF, the Parties have duly executed this Amendment effective as of the 8th day of August, 2002. 

	Antares Pharma IPL AG	 	 	 	 
	

	
 	

 	
 	

/s/        

	Place and Date	 	By:	 	 
	 	 	Its:	 	CEO and President
	
BioSante Pharmaceuticals, Inc.	
 	

 	
 	

 
	

Lincolnshire, IL            8/8/02
	
 	

 	
 	

/s/  STEPHEN M. SIMES      

	Place and Date	 	By:	 	Stephen M. Simes
	 	 	Its:	 	President and CEO

5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00042-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00042-of-00352.parquet"}]]